The data from the study indicated that PMX-60056 met the endpoints of the research regarding both the reversal of varying heparin levels as well as allowing re-anticoagulation and re-reversal. The data will allow the company to support the development of a Phase 2 clinical trial in surgical patients. This is clearly an indication that PolyMedix is evolving into a pioneer in their field and is not only a friend of savvy investors, but also the medical sector as a whole.
The results of the Phase 1B/2 clinical study displayed that PMX-60056 reversed up to 350 U/kg of heparin, did not interfere with a second anticoagulation and was generally well tolerated with no serious adverse events reported during the study.
Dr. Eric McAllister, who serves as the Vice President of Clinical Development and Chief Medical Officer of PolyMedix was quoted as saying, “We believe the reductions in blood pressure seen in this study are due to an excess of PMX-60056 after the last dose, when most heparin had already been neutralized. This study has provided information that will help us better quantify the dosing of PMX-60056 in our planned Phase 2 clinical trial to reverse heparin in cardiothoracic surgery.”
Leading the way at PolyMedix is Nicholas Landekic who serves as the company’s President and CEO. When asked his thoughts on the results of this study, Landekic stated, “We believe these results support further study of the use of PMX-60056 in cardiothoracic and other surgical procedures. We are very proud to have discovered this unique compound for development as an anticoagulant reversing agent, and are looking forward to moving PMX-60056 into more advanced clinical studies.”
Currently, PolyMedix is trading in the $0.90 range. With the success of this study, PolyMedix is a company to keep an eye on.
To learn more about PolyMedix, visit the company website at: www.polymedix.com.